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Background:  C-type natriuretic peptide (CNP) is a 22-amino-acid peptide produced mainly in the endothelium with potent cardiac unloading, 
anti-fibrotic and blood pressure lowering actions, but minimal renal actions. Based on our previous knowledge, we recently designed a natriuretic 
peptide CBA-NP, by fusing a 6 aa sequence (KVLRRH) from BNP to the C-terminus and a 5 aa sequence (RMDRI) from ANP to the N-terminus 
of CNP. Our objective was to determine the anti-fibrotic and cardiohumoral effects of this designer chimeric peptide in a rat model of diabetic 
cardiomyopathy.
Methods:  Three groups of male Wistar rats six rats per group, normal control, diabetic control, and diabetic control treated with CBA-NP were 
used. One dose of streptozotocin was administered to induce diabetes. One month after induction of diabetes, ALZET pumps filled with a 0.1μg/kg/
min dose of CBA-NP or with saline as control were serially implanted subcutaneously every 14 days over the course of 2 months. Cardiac function 
was assessed by echocardiography, neurohormones were measured by RIA, fibrosis was determined by picrosirius red staining, and ultrastructural 
features were assessed by electron microscopy.
Results:  CBA-NP treatment attenuated left ventricular (LV) hypertrophy (LV/body weight ratio) (0.24±.01 mg/g body weight) compared to diabetic 
control (0.26±.01) and was comparable to normal control (0.24±.01). Both LV interstitial and perivascular percent fibrosis were significantly 
(p<0.05) reduced in the CBA-NP treated group from 3.27 to 1.80 and 3.87 to1.77 respectively as compared to diabetic control. Ejection fraction 
and fractional shortening were significantly (p<0.05) improved from 78.0% to 84.0% and 41% to 48% respectively after the CBA-NP treatment 
compared to diabetic control. There was a significant (p<0.05) decrease in plasma renin, aldosterone and BNP while plasma cGMP increased in the 
treated group compared to the untreated group.
Conclusions:  These studies suggest that CBA-NP treatment attenuated LV hypertrophy, reduced cardiac fibrosis, and improved cardiac function 
with suppression of renin and aldosterone suggesting a potential therapeutic benefit in diabetic cardiomyopathy.
